Molecular Diagnostics

Molecular Diagnostics

Global Molecular Diagnostics Market to Reach $20 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Molecular Diagnostics estimated at US$10.4 Billion in the year 2020, is projected to reach a revised size of US$20 Billion by 2027, growing at a CAGR of 9.8% over the analysis period 2020-2027. Reagents & Kits, one of the segments analyzed in the report, is projected to record a 10.4% CAGR and reach US$11.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 8.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $4.4 Billion, While China is Forecast to Grow at 10.9% CAGR
The Molecular Diagnostics market in the U.S. is estimated at US$4.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2027 trailing a CAGR of 10.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027.

Software & Service Segment to Record 9.3% CAGR
In the global Software & Service segment, USA, Canada, Japan, China and Europe will drive the 9.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1 Billion in the year 2020 will reach a projected size of US$1.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 9.9% CAGR through the analysis period.

Select Competitors (Total 84 Featured) -

  • Abbott Laboratories
  • Abbott Molecular
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Cepheid
  • F. Hoffmann-La Roche Ltd.
  • Grifols International, S.A.
  • Hologic, Inc.
  • QIAGEN N.V.
  • QuestDiagnostics, Inc.
  • Siemens Healthcare GmbH
  • Tecan Group Ltd.
  • The ELITechGroup
  • Thermo Fisher Scientific
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of COVID-19 Pandemic and Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
Pandemic Puts Intense Pressure on Healthcare Systems & Products Worldwide
Molecular Diagnostics Receive Healthy Booster from COVID-19 Tests
Total Number of COVID-19 Tests Conducted and Tests Per Million Population in Most Impacted Countries: As on September 27, 2021
Molecular Point-of-Care Tests for COVID-19 Witness Rapid Growth
Molecular RT-PCR Emerges as the Frontline Technology for Testing COVID-19
Select Commercial Molecular Tests for COVID-19
CRISPR Emerges as Cutting-Edge Biotechnology in COVID-19 Diagnostic Market
COVID-19 Affects Demand for Non- COVID Diagnostics
Point of Care (POC) Molecular Diagnostics – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Molecular Diagnostics: Leveraging Molecular Technologies to Monitor Human Diseases
Types of Molecular Diagnostics Tests
An Introduction to Point of Care (POC) Molecular Diagnostics
Molecular Testing Mechanisms
Molecular Vs Non-Molecular POCT
Global Market Prospects & Outlook
PCR Technology Leads the MDx Market
Infectious Diseases: The Largest Application Market
Reagents and Kits Dominate the Molecular Diagnostics Market
Developing Countries Present Strong Growth Prospects
Competition
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Point of Care Diagnostics Augurs Well for Molecular POC Diagnostics Market
Emphasis on Decentralized Diagnostics Presents Opportunity for POC Testing
Faster Screening Necessitates Point-of-care Diagnostics for COVID-19 Pandemic
Growing Prevalence of Infectious Diseases Spurs Need for POC Molecular Diagnostics
Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
Rising Prevalence of Respiratory Infections to Drive Need for POC Molecular Diagnostics
Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
Rise in Pollution Levels Trigger Increase in Respiratory Diseases, Driving Market Opportunities
Percentage Share Breakdown of Global Deaths Linked to Air Pollution
Air Pollution Levels (PM2.5 Concentration (μg/m³) for Major Countries Worldwide for 2020
Rising Cancer Incidence Drives Focus onto POC Molecular Diagnostics
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020
Number of New Cancer Cases and Deaths (in Million) by Region for 2020
Rising Incidence of Hospital Acquired Infections (HAIs) Propels Demand for POC Molecular Diagnostics
Sustained Threat of HIV and Sexually Transmitted Diseases Amplify Need for POC Molecular Diagnostics
Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2020
Number of AIDS-Related Deaths (in Thousands) by Region for 2018
Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
Home HIV Testing Emerges as a Lucrative Option
Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
Hepatitis B Prevalence Worldwide by Region
Demand Continues to Surge for CLIA-Waived Molecular POC Tests
Advancements in POC for Molecular Diagnostics to Drive Market Growth
Nanotechnology Facilitates Development of for POC Molecular Diagnostics
Healthcare Needs of the World’s Aging Population: Potential Opportunity in Store
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Increase in Healthcare Spending in Emerging Markets to Propel Demand for POC Molecular Diagnostics
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
Elderly Healthcare Expenditure as a % of GDP for 1970, 2010 and 2050
Challenges Facing POC Molecular Diagnostics Market
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for PCR-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Genetic Sequencing-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Hybridization-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Microarray-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Assisted Living Healthcare Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 24: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 27: World 15-Year Perspective for Decentralized Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 28: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 29: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 30: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 31: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 32: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 33: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 34: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 35: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 36: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 37: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 39: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 40: World Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 41: World Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 42: World 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 43: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 44: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 45: USA 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 46: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 47: USA Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 48: USA 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 49: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 51: USA 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
CANADA
TABLE 52: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 54: Canada 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 55: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 57: Canada 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 58: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 59: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 60: Canada 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
JAPAN
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 61: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 63: Japan 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 64: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 65: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 66: Japan 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 67: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 69: Japan 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
CHINA
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 70: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 71: China Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 72: China 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 73: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 74: China Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 75: China 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 76: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 77: China Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 78: China 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
EUROPE
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 79: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 81: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 82: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 83: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 84: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 85: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 87: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
TABLE 88: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 89: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 90: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
FRANCE
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 91: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: France Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 93: France 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 94: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 95: France Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 96: France 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 97: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 98: France Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 99: France 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
GERMANY
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 100: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 101: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 102: Germany 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 103: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 104: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 105: Germany 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 106: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 107: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 108: Germany 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
ITALY
TABLE 109: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 110: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 111: Italy 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 112: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 113: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 114: Italy 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 115: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 116: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 117: Italy 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
UNITED KINGDOM
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 118: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 119: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 120: UK 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 121: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 122: UK Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 123: UK 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 124: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 125: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 126: UK 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
SPAIN
TABLE 127: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 128: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 129: Spain 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 130: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 131: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 132: Spain 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 133: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 134: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 135: Spain 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
RUSSIA
TABLE 136: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 137: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 138: Russia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 139: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 140: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 141: Russia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 142: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 143: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 144: Russia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 145: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 146: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 147: Rest of Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 148: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 149: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 150: Rest of Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 151: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 152: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 153: Rest of Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 154: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 155: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 156: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 157: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 158: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 159: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 160: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 161: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 162: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
TABLE 163: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 164: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 165: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
AUSTRALIA
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
TABLE 166: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 167: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 168: Australia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 169: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 170: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 171: Australia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 172: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 173: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 174: Australia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
INDIA
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
TABLE 175: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 176: India Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 177: India 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 178: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 179: India Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 180: India 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 181: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 182: India Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 183: India 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
SOUTH KOREA
TABLE 184: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 185: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 186: South Korea 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 187: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 188: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 189: South Korea 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 190: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 191: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 192: South Korea 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
TABLE 193: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 194: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 195: Rest of Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 196: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 197: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 198: Rest of Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 199: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 200: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 201: Rest of Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
LATIN AMERICA
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
TABLE 202: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 203: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 204: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 205: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 206: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 207: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 208: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 209: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 210: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
TABLE 211: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 212: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 213: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
ARGENTINA
TABLE 214: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 215: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 216: Argentina 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 217: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 218: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 219: Argentina 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 220: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 221: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 222: Argentina 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
BRAZIL
TABLE 223: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 224: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 225: Brazil 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 226: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 227: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 228: Brazil 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 229: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 230: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 231: Brazil 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
MEXICO
TABLE 232: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 233: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 234: Mexico 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 235: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 236: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 237: Mexico 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 238: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 239: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 240: Mexico 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
REST OF LATIN AMERICA
TABLE 241: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 242: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 243: Rest of Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 244: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 245: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 246: Rest of Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 247: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 248: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 249: Rest of Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
MIDDLE EAST
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
TABLE 250: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 251: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 252: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 253: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 254: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 255: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 256: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 257: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 258: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
TABLE 259: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 260: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 261: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
IRAN
TABLE 262: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 263: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 264: Iran 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 265: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 266: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 267: Iran 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 268: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 269: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 270: Iran 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
ISRAEL
TABLE 271: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 272: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 273: Israel 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 274: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 275: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 276: Israel 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 277: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 278: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 279: Israel 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
SAUDI ARABIA
TABLE 280: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 281: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 282: Saudi Arabia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 283: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 284: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 285: Saudi Arabia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 286: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 287: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 288: Saudi Arabia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
UNITED ARAB EMIRATES
TABLE 289: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 290: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 291: UAE 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 292: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 293: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 294: UAE 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 295: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 296: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 297: UAE 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
REST OF MIDDLE EAST
TABLE 298: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 299: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 300: Rest of Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 301: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 302: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 303: Rest of Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 304: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 305: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 306: Rest of Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
AFRICA
Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
TABLE 307: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 308: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 309: Africa 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2012, 2021 & 2027
TABLE 310: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 311: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 312: Africa 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2012, 2021 & 2027
TABLE 313: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 314: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 315: Africa 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2012, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 64

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings